Calamos Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Calamos Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,458	Closed	-$14K	–	993
2020 Q4	$14K	Hold	20,458	–	–	﹤0.01%	735
2020 Q3	$46K	Hold	20,458	–	–	﹤0.01%	699
2020 Q2	$73K	Hold	20,458	–	–	﹤0.01%	702
2020 Q1	$78K	Hold	20,458	–	–	﹤0.01%	693
2019 Q4	$62K	Buy	+20,458	New	+$53.2K	﹤0.01%	763

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Calamos Advisors's BMY.RT Position: Q1 2021 in Review

Calamos Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 20,458 shares — an estimated $14K sold.

Calamos Advisors first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $78K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Calamos Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Calamos Advisors sold 20,458 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $14K.
Calamos Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Calamos Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $78K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Calamos Advisors's 13F filing for Q1 2021, filed 12 Apr 2021.